KIT and neoplasm: In a phase II trial that evaluated everolimus in unselected patients with refractory testicular germ-cell tumors, no objective response was observed with a PFS rate at 3 months of 40%.18 Finally, three patients in SHIVA01 seemed to benefit from MTAs that targeted epidermal growth factor receptor, KIT, and BRAF mutations, which are clinically validated targets in other tumor types.19-22 Of interest, the patient with BRAF V600E–mutated colorectal cancer experienced an unusual response to vemurafenib.